Cellectar Biosciences (CLRB) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.19, +0.85% vs the prior close of $1.18.
- Volume 379.00K shares, 5.2x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CLRB rises 0.8% to $1.19 on 5.2x normal volume. Closed at $1.19, +0.85% vs the prior close of $1.18. Day range $1.15–$1.27, opened at $1.21.
CLRB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — CLRB rises 0.8% to $1.19 on 5.2x normal volume
- Closed at $1.19, +0.85% vs the prior close of $1.18. Day range $1.15–$1.27, opened at $1.21.
- Volume was 379.00K shares, 5.2x its 50-day average of 72.26K — unusually heavy trading.
- Price is -45.6% vs its 50-day average ($2.19) and -56.8% vs its 200-day average ($2.75).
- 52-week range $1.15–$5.07; today's close sits at 1% of that range, 76.5% below the 52-week high.
Oct 14, 2026 — CLRB slides 15.1% to $1.18, a 52-week low on 6.0x normal volume
- Closed at $1.18, -15.11% vs the prior close of $1.39. Day range $1.15–$1.47, opened at $1.44.
- Volume was 393.60K shares, 6.0x its 50-day average of 65.17K — unusually heavy trading.
- Price is -46.7% vs its 50-day average ($2.21) and -57.2% vs its 200-day average ($2.76).
- 52-week range $1.15–$5.07; today's close sits at 1% of that range, 76.7% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CLRB dips 2.8% to $1.39, a 52-week low on 9.6x normal volume
- Closed at $1.39, -2.80% vs the prior close of $1.43. Day range $1.36–$1.60, opened at $1.55.
- Volume was 534.50K shares, 9.6x its 50-day average of 55.44K — unusually heavy trading.
- Price is -38.0% vs its 50-day average ($2.24) and -49.7% vs its 200-day average ($2.77).
- 52-week range $1.34–$5.07; today's close sits at 1% of that range, 72.6% below the 52-week high.
Oct 12, 2026 — CLRB dips 1.4% to $1.43 on 3.4x normal volume
- Closed at $1.43, -1.38% vs the prior close of $1.45. Day range $1.40–$1.47, opened at $1.45.
- Volume was 186.10K shares, 3.4x its 50-day average of 54.30K — unusually heavy trading.
- Price is -36.9% vs its 50-day average ($2.27) and -48.4% vs its 200-day average ($2.77).
- 52-week range $1.34–$5.07; today's close sits at 2% of that range, 71.8% below the 52-week high.
Oct 9, 2026 — CLRB jumps 3.6% to $1.45
- Closed at $1.45, +3.57% vs the prior close of $1.40. Day range $1.37–$1.49, opened at $1.41.
- Volume was 91.50K shares, 1.7x its 50-day average of 53.07K.
- Price is -36.7% vs its 50-day average ($2.29) and -47.8% vs its 200-day average ($2.78).
- 52-week range $1.34–$5.07; today's close sits at 3% of that range, 71.4% below the 52-week high.
Oct 8, 2026 — CLRB slides 7.3% to $1.40, a 52-week low on 3.3x normal volume
- Closed at $1.40, -7.28% vs the prior close of $1.51. Day range $1.34–$1.57, opened at $1.57.
- Volume was 169.60K shares, 3.3x its 50-day average of 51.38K — unusually heavy trading.
- Price is -39.4% vs its 50-day average ($2.31) and -49.7% vs its 200-day average ($2.79).
- 52-week range $1.34–$5.19; today's close sits at 2% of that range, 73.0% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — CLRB ends flat (+0.0%) to $1.51, 4 down days in a row
- Closed at $1.51, +0.00% vs the prior close of $1.51. Day range $1.47–$1.62, opened at $1.55.
- Volume was 42.60K shares, 0.8x its 50-day average of 51.54K.
- Price is -35.3% vs its 50-day average ($2.33) and -45.9% vs its 200-day average ($2.79).
- 52-week range $1.46–$5.59; today's close sits at 1% of that range, 73.0% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — CLRB slides 9.6% to $1.51, a 52-week low on 4.6x normal volume
- Closed at $1.51, -9.58% vs the prior close of $1.67. Day range $1.46–$1.73, opened at $1.66.
- Volume was 219.30K shares, 4.6x its 50-day average of 47.68K — unusually heavy trading.
- Price is -35.8% vs its 50-day average ($2.35) and -46.0% vs its 200-day average ($2.80).
- 52-week range $1.46–$6.52; today's close sits at 1% of that range, 76.8% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — CLRB slides 6.2% to $1.67, a 52-week low
- Closed at $1.67, -6.18% vs the prior close of $1.78. Day range $1.67–$1.79, opened at $1.79.
- Volume was 60.70K shares, 1.3x its 50-day average of 47.19K.
- Price is -29.6% vs its 50-day average ($2.37) and -40.5% vs its 200-day average ($2.80).
- 52-week range $1.67–$6.52; today's close sits at 0% of that range, 74.4% below the 52-week high.
Oct 2, 2026 — CLRB slides 4.8% to $1.78, a 52-week low
- Closed at $1.78, -4.81% vs the prior close of $1.87. Day range $1.78–$1.98, opened at $1.95.
- Volume was 47.60K shares, 1.0x its 50-day average of 46.96K.
- Price is -25.4% vs its 50-day average ($2.39) and -36.7% vs its 200-day average ($2.81).
- 52-week range $1.78–$6.52; today's close sits at 0% of that range, 72.7% below the 52-week high.
CLRB latest news & SEC filings
Every SEC filing by or about CLRB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$6.93M (prior year -$5.45M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.57 (prior year -$3.39) (loss narrowed vs Jun 30, 2025)
Aug 4, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 10, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade CLRB
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 4, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.20% (largest 15.1%). That is a volatile stock.
- Liquidity: about 145.50K shares (≈$173.15K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.19 vs a range of $1.15–$5.07 (1% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:30 on Jun 24, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 2 open-market buys, 1 sales; latest: James V Caruso bought 8,680 shares on May 7, 2026.
- Latest filings: 8-K Aug 13, 2026; 10-Q Aug 13, 2026; 8-K Jul 10, 2026.
- Share count: 9.45M shares outstanding (Aug 11, 2026), +196.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
CLRB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.21 | 1.27 | 1.15 | 1.19 | 379.00K |
| Oct 14, 2026 | 1.44 | 1.47 | 1.15 | 1.18 | 393.60K |
| Oct 13, 2026 | 1.55 | 1.60 | 1.36 | 1.39 | 534.50K |
| Oct 12, 2026 | 1.45 | 1.47 | 1.40 | 1.43 | 186.10K |
| Oct 9, 2026 | 1.41 | 1.49 | 1.37 | 1.45 | 91.50K |
| Oct 8, 2026 | 1.57 | 1.57 | 1.34 | 1.40 | 169.60K |
| Oct 7, 2026 | 1.55 | 1.62 | 1.47 | 1.51 | 42.60K |
| Oct 6, 2026 | 1.66 | 1.73 | 1.46 | 1.51 | 219.30K |
| Oct 5, 2026 | 1.79 | 1.79 | 1.67 | 1.67 | 60.70K |
| Oct 2, 2026 | 1.95 | 1.98 | 1.78 | 1.78 | 47.60K |
| Oct 1, 2026 | 1.87 | 1.87 | 1.82 | 1.87 | 29.90K |
| Sep 30, 2026 | 1.92 | 1.92 | 1.82 | 1.84 | 74.90K |
| Sep 29, 2026 | 1.98 | 1.98 | 1.81 | 1.82 | 85.60K |
| Sep 28, 2026 | 1.80 | 1.89 | 1.80 | 1.83 | 58.90K |
| Sep 25, 2026 | 2.07 | 2.09 | 1.80 | 1.80 | 123.10K |
| Sep 24, 2026 | 2.13 | 2.15 | 1.96 | 2.08 | 55.50K |
| Sep 23, 2026 | 2.25 | 2.31 | 2.06 | 2.09 | 72.90K |
| Sep 22, 2026 | 2.36 | 2.37 | 2.17 | 2.23 | 161.20K |
| Sep 21, 2026 | 2.37 | 2.42 | 2.35 | 2.35 | 50.00K |
| Sep 18, 2026 | 2.39 | 2.44 | 2.37 | 2.38 | 73.60K |
About Cellectar Biosciences
Cellectar Biosciences (CLRB) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in FLORHAM PARK, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1279704.
CLRB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| James V Caruso | President & CEO | Jul 8, 2026 |
| Asher Chanan-Khan | Director | Jul 8, 2026 |
| Frederick W Driscoll | Director | Jul 8, 2026 |
| Andrew Gu | Director | Jul 8, 2026 |
| John Neis | Director | Jul 8, 2026 |
| Douglas J Swirsky | Director | Jul 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James V Caruso | President & CEO | Jul 8, 2026 |
| Chad J Kolean | CFO | Jul 8, 2026 |
| Jarrod Longcor | Chief Operating Officer | Jul 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 7, 2026 | James V Caruso | Buy | 8,680 | $2.88 |
| May 7, 2026 | Jarrod Longcor | Buy | 8,680 | $2.88 |
| Dec 12, 2025 | John Neis | Sale | 198 | $3.70 |
CLRB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-21.79M | -8.35 | $-23.12M |
| Dec 31, 2024 | — | $-44.58M | -41.89 | $-47.58M |
| Dec 31, 2023 | — | $-42.77M | -3.50 | $-32.38M |
| Dec 31, 2022 | — | $-28.60M | -4.05 | $-25.22M |
| Dec 31, 2021 | — | $-24.12M | -4.35 | $-22.57M |
Latest balance sheet: total assets $36.64M, total liabilities $6.77M, cash $33.99M (as of Jun 30, 2026).
CLRB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $2.48 |
| May 14, 2026 | 8-K Item 2.02 (results) | $3.20 |
| Mar 4, 2026 | 8-K Item 2.02 (results) | $2.90 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $2.87 |
| Oct 10, 2025 | 8-K Item 2.02 (results) | $4.64 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $4.42 |
| May 13, 2025 | 8-K Item 2.02 (results) | $7.20 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $9.00 |
| Nov 18, 2024 | 8-K Item 2.02 (results) | $53.10 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| Jul 23, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on CLRB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.